LETTER Questions Regarding Variants in ADIPOQ in Maternal **Circulating Adipokine Profile in Gestational Diabetes** Mellitus [Letter]

Novaria Sari Dewi Panjaitan ^[b], Sela Septima Mariya¹, Armedy Ronny Hasugian ^[b]

¹Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Cibinong - Bogor, West Java, Indonesia; ²Research Center of Preclinical and Clinical Medicine, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Cibinong - Bogor, West Java, Indonesia

Correspondence: Novaria Sari Dewi Panjaitan, Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Jl. Raya Bogor No. 490, Cibinong – Bogor, West Java, Indonesia, Email nova014@brin.go.id

Dear editor

The altered secretion or increased levels of released adipokine have been reported to contribute to several metabolic diseases, such as diabetes mellitus, obesity, and cardiovascular disorders.¹ Specific to diabetogenic adipokine, aprosin was recently reported to be the novel adipokine in diabetes mellitus cases, playing a potent role in inducing the production of hepatic glucose and influencing the appetite levels of the patients. In addition, a previous study mentioned that the polymorphism of ADIPOO rs17366743 was one of the integrating common risk factors, besides CCL20 rs6749704, TCF7L2 rs114758349, and CCL2 rs1024611, associated with the prediction of type 2 diabetes on the Eurasian continent.²

The study performed by Tangjittipokin et al was recently read and reviewed by our group. We do feel gratitude towards the authors of this article.³ However, a few discussions provided here could, hopefully, be considered as insightful input in their future studies. The study was performed in order to investigate the association of ADIPOQ gene polymorphisms in pregnant women who could probably be diagnosed with gestational diabetes mellitus.³ However, the polymorphisms of the ADIPOO gene were detected from rs266729, rs2241766, and rs1501299. This study detected polymorphisms that were not included among those playing an important role as a risk factor in a previous report.² In addition, we noticed that there were several types of adipokine serums detected in their study, such as adiponectin, adipsin/factor D, lipocalin, total PAI-1, and resistin.³ However, a previous study stated that circulating aprosin, the adipokine serum, was reviewed as a promising candidate for both novel pharmacological treatment strategies and diagnostic tools in clinical cases of diabetes mellitus.¹ Therefore, the detection of aprosin was recommended to be included in future studies to reach a comprehensive conclusion.

This study demonstrated that maternal age, pre-pregnancy BMI, and increasing body weight not associated with gestational diabetes mellitus could not be utilized as predictive factors. Moreover, the expression of adiponectin receptors and methylation of the adiponectin gene promoter have been reported to be associated in the development of dementia in patients diagnosed with Alzheimer's disease.⁴ However, the expression of adiponectin receptors in gestational diabetes mellitus patients could not be detected, while a study on methylation has been reported previously.⁵ An additional thoughtful response to this interesting study is that the detection of polymorphisms of the ADIPOO gene in the study model of Macaca fascicularis was suggested to be performed in future research, such as that performed in a previous study.⁶

Acknowledgments

All authors would like to acknowledge the authors of the discussed article, Tangjittipokin et al, for their fruitful research work, which was recently reported in the Journal of Multidisciplinary Healthcare. In addition, all authors would like to acknowledge Dr. Sunarno for his ongoing support for researchers in the Center of Biomedical Research, BRIN.

429

CO OS © 2023 Panjaitan et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www .dovepress.com/ erms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Disclosure

All authors report no conflicts of interest in this communication.

References

- 1. Farrag M, Ait Eldjoudi D, González-Rodríguez M, et al. Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects. *Front Endocrinol.* 2023;13:1–17. doi:10.3389/fendo.2022.1101091
- 2. Timasheva Y, Balkhiyarova Z, Avzaletdinova D, et al. Integrating common risk factors with polygenic scores improves the prediction of type 2 diabetes. *Int J Mol Sci.* 2023;24:984. doi:10.3390/ijms24020984
- 3. Tangjittipokin W, Narkdontri T, Teerawattanapong N, Thanatummatis B, Sunsaneevithayakul P, Boriboonhirunsarn D. The variants in ADIPOQ are associated with maternal circulating adipokine profile in gestational diabetes mellitus. *J Multidiscip Healthc*. 2023;16:309–319. doi:10.2147/JMDH.S396238
- 4. Kaiyrlykyzy A, Umbayev B, Masoud AR, et al. Circulating adiponectin levels, expression of adiponectin receptors, and methylation of adiponectin gene promoter in relation to Alzheimer's disease. *BMC Med Genom.* 2022;15(1):1–10. doi:10.1186/s12920-022-01420-8
- 5. Wang WJ, Huang R, Zheng T, et al. Genome-wide placental gene methylations in gestational diabetes mellitus, fetal growth and metabolic health biomarkers in cord blood. *Front Endocrinol.* 2022;13:1–12. doi:10.3389/fendo.2022.875180
- 6. Mariya SS, Dewi FN, Villiandra V, et al. Isolation and characterization of c-c chemokine ligand 7 (Ccl7) in cynomolgus macaques. *HAYATI J Biosci*. 2019;26(3):129–132. doi:10.4308/hjb.26.3.129

Dove Medical Press encourages responsible, free and frank academic debate. The contentTxt of the Journal of Multidisciplinary Healthcare 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Journal of Multidisciplinary Healthcare editors. While all reasonable steps have been taken to confirm the contentTxt of each letter, Dove Medical Press accepts no liability in respect of the contentTxt of any letter, nor is it responsible for the contentTxt and accuracy of any letter to the editor.

Journal of Multidisciplinary Healthcare

Dovepress

Publish your work in this journal

The Journal of Multidisciplinary Healthcare is an international, peer-reviewed open-access journal that aims to represent and publish research in healthcare areas delivered by practitioners of different disciplines. This includes studies and reviews conducted by multidisciplinary teams as well as research which evaluates the results or conduct of such teams or healthcare processes in general. The journal covers a very wide range of areas and welcomes submissions from practitioners at all levels, from all over the world. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/journal-of-inflammation-research-journal

https://doi.org/10.2147/JMDH.S406812